References
- Wang J, Nagueh SF. Current perspectives on cardiac function in patients with diastolic heart failure. Circulation 2009;119:1146–57.
- Kameyama T, Chen Z, Bell SP, et al. Mechanoenergetic alterations during the transition from cardiac hypertrophy to failure in Dahl salt-sensitive rats. Circulation 1998;98:2919–29.
- Doi R, Masuyama T, Yamamoto K, et al. Development of different phenotypes of hypertensive heart failure: Systolic versus diastolic failure in Dahl salt-sensitive rats. J Hypertens 2000;18:111–20.
- Sunga PS. Rabkin SW. Angiotensin II-induced protein phosphorylation in the hypertrophic heart of the Dahl rat. Hypertension 1992;20:633–42. Available at: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1428115
- Campese VM. Salt sensitivity in hypertension. Renal and cardiovascular implications. Hypertension 1994;23:531–50. Available at: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=8144222
- Deng AY. Genetics of systolic and diastolic heart failure. J Hypertens 2015;33:3–13. Available at: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=25380161
- Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44–57.
- Guo P, Nishiyama A, Rahman M, et al. Contribution of reactive oxygen species to the pathogenesis of left ventricular failure in Dahl salt-sensitive hypertensive rats: Effects of angiotensin II blockade. J Hypertens 2006;24:1097–104.
- Horie T, Ono K, Nishi H, et al. MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes. Biochem Biophys Res Commun 2009;389:315–20.
- Ichihara S, Obata K, Yamada Y, et al. Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors. J Mol Cell Cardiol 2006;41:318–29.
- Iwanaga Y, Kihara Y, Inagaki K, et al. Differential effects of angiotensin II versus endothelin-1 inhibitions in hypertrophic left ventricular myocardium during transition to heart failure. Circulation 2001;104:606–12. Available at: http://gw2jh3xr2c.search.serialssolutions.com?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:medc&rft.genre=article&rft_id=info:doi/&rft_id=info:pmid/11479261&rft.issn=0009-7322&rft.volume=104&rft.issue=5&rft.spage=606&rft.pages=606-12&rft.date=2001&rft.jtitle=Circulation&rft.atitle=Differential+effects+of+angiotensin+II+versus+endothelin-1+inhibitions+in+hypertrophic+left+ventricular+myocardium+during+transition+to+heart+failure.&rft.aulast=Iwanaga
- Kanazawa H, Ieda M, Kimura K, et al. Heart failure causes cholinergic transdifferentiation of cardiac sympathetic nerves via gp130-signaling cytokines in rodents. J Clin Invest 2010;120:408–21.
- Kato T, Niizuma S, Inuzuka Y, et al. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ Heart Fail 2010;3:420–30.
- Kim S, Yoshiyama M, Izumi Y, et al. Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. Circulation 2001;103:148–54.
- Kobayashi N, Hara K, Higashi T, Matsuoka H. Effects of imidapril on endothelin-1 and ACE gene expression in failing hearts of salt-sensitive hypertensive rats. Am J Hypertens 2000;13:1088–96.
- Kobayashi N, Horinaka S, Mita S, et al. Critical role of Rho-kinase pathway for cardiac performance and remodeling in failing rat hearts. Cardiovasc Res 2002;55:757–67.
- Kobayashi N, Horinaka S, Mita S, et al. Aminoguanidine inhibits mitogen-activated protein kinase and improves cardiac performance and cardiovascular remodeling in failing hearts of salt-sensitive hypertensive rats. J Hypertens 2002;20:2475–85.
- Kong SW, Bodyak N, Yue P, et al. Genetic expression profiles during physiological and pathological cardiac hypertrophy and heart failure in rats. Physiol Genomics 2005;21:34–42.
- Miyachi M, Yazawa H, Furukawa M, et al. Exercise training alters left ventricular geometry and attenuates heart failure in dahl salt-sensitive hypertensive rats. Hypertension 2009;53:701–07.
- Nagata K, Obata K, Xu J, et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 2006;47:656–64.
- Nishikawa N, Yamamoto K, Sakata Y, et al. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. Cardiovasc Res 2003;57:766–74.
- Nishikimi T, Tadokoro K, Mori Y, et al. Ventricular adrenomedullin system in the transition from LVH to heart failure in rats. Hypertension 2003;41:512–18.
- Nishikimi T, Mori Y, Ishimura K, et al. Chronic effect of combined treatment with omapatrilat and adrenomedullin on the progression of heart failure in rats. Am J Hypertens 2006;19:1039–48.
- Nishio M, Sakata Y, Mano T, et al. Therapeutic effects of angiotensin II type 1 receptor blocker at an advanced stage of hypertensive diastolic heart failure. J Hypertens 2007;25:455–61.
- Nishizawa T, Cheng XW, Jin Z, et al. Ca(2+) channel blocker benidipine promotes coronary angiogenesis and reduces both left-ventricular diastolic stiffness and mortality in hypertensive rats. J Hypertens 2010;28:1515–26.
- Ohno T, Kobayashi N, Yoshida K, et al. Cardioprotective effect of benidipine on cardiac performance and remodeling in failing rat hearts. Am J Hypertens 2008;21:224–30.
- Okayama H, Hamada M, Kawakami H, et al. Alterations in expression of sarcoplasmic reticulum gene in Dahl rats during the transition from compensatory myocardial hypertrophy to heart failure. J Hypertens 1997;15:1767–74.
- Saka M, Obata K, Ichihara S, et al. Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure. J Cardiovasc Pharmacol 2006;47:770–79.
- Sakata Y, Masuyama T, Yamamoto K, et al. Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats. Circulation 2000;102:2269–2275. Available at: http://gw2jh3xr2c.search.serialssolutions.com?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:med4&rft.genre=article&rft_id=info:doi/&rft_id=info:pmid/11056104&rft.issn=0009-7322&rft.volume=102&rft.issue=18&rft.spage=2269&rft.pages=2269-75&rft.date=2000&rft.jtitle=Circulation&rft.atitle=Calcineurin+inhibitor+attenuates+left+ventricular+hypertrophy%2C+leading+to+prevention+of+heart+failure+in+hypertensive+rats.&rft.aulast=Sakata
- Sakata Y, Yamamoto K, Masuyama T, et al. Ventricular production of natriuretic peptides and ventricular structural remodeling in hypertensive heart failure. J Hypertens 2001;19:1905–12.
- Sakata Y, Yamamoto K, Mano T, et al. Angiotensin II type 1 receptor blockade prevents diastolic heart failure through modulation of Ca(2+) regulatory proteins and extracellular matrix. J Hypertens 2003;21:1737–45.
- Sakata Y, Yamamoto K, Mano T, et al. Temocapril prevents transition to diastolic heart failure in rats even if initiated after appearance of LV hypertrophy and diastolic dysfunction. Cardiovasc Res 2003;57:757–65.
- Sakata Y, Yamamoto K, Mano T, et al. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation 2004;109:2143–49.
- Tanada Y, Shioi T, Kato T, et al. Branched-chain amino acids ameliorate heart failure with cardiac cachexia in rats. Life Sci 2015;137:20–27.
- Wake R, Kim-Mitsuyama S, Izumi Y, et al. Beneficial effect of candesartan on rat diastolic heart failure. J Pharmacol Sci 2005;98:372–79.
- Xu J, Nagata K, Obata K, et al. Nicorandil promotes myocardial capillary and arteriolar growth in the failing heart of Dahl salt-sensitive hypertensive rats. Hypertension 2005;46:719–24.
- Yamada T, Nagata K, Cheng XW, et al. Long-term administration of nifedipine attenuates cardiac remodeling and diastolic heart failure in hypertensive rats. Eur J Pharmacol 2009;615:163–70.
- Yamamoto K, Masuyama T, Sakata Y, et al. Local neurohumoral regulation in the transition to isolated diastolic heart failure in hypertensive heart disease: Absence of AT1 receptor downregulation and “overdrive” of the endothelin system. Cardiovasc Res 2000;46:421–32.
- Yamamoto K, Masuyama T, Sakata Y, et al. Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts. Cardiovasc Res 2000;47:274–83.
- Yamamoto K, Takahashi Y, Mano T, et al. N-methylethanolamine attenuates cardiac fibrosis and improves diastolic function: inhibition of phospholipase D as a possible mechanism. Eur Heart J 2004;25:1221–29.
- Yamamoto K, Mano T, Yoshida J, et al. ACE inhibitor and angiotensin II type 1 receptor blocker differently regulate ventricular fibrosis in hypertensive diastolic heart failure. J Hypertens 2005;23:393–400.
- Yoshida J, Yamamoto K, Mano T, et al. AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure. Hypertension 2004;43:686–91.
- Yazawa H, Miyachi M, Furukawa M, et al. Angiotensin-converting enzyme inhibition promotes coronary angiogenesis in the failing heart of Dahl salt-sensitive hypertensive rats. J Card Fail 2011;17:1041–50.
- Guo T-S, Zhang J, Mu -J-J, et al. High-salt intake suppressed microRNA-133a expression in Dahl SS rat myocardium. Int J Mol Sci 2014;15:10794–805.
- Kapur NK. Transforming Growth Factor-: governing the Transition From Inflammation to Fibrosis in Heart Failure With Preserved Left Ventricular Function. Circ Hear Fail 2011;4:5–7.
- Nakamura T, Fukuda M, Kataoka K, et al. Eplerenone potentiates protective effects of amlodipine against cardiovascular injury in salt-sensitive hypertensive rats. Hypertens Res 2011;34:817–24.
- Funck RC, Wilke A, Rupp H, Brilla CG. Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. Adv Exp Med Biol 1997;432:35–44.
- Ferrario CM. Cardiac remodelling and RAS inhibition. Ther Adv Cardiovasc Dis 2016.
- Chatzikyriakou SV, Tziakas DN, Chalikias GK, et al. Chronic heart failure patients with high collagen type I degradation marker levels benefit more with ACE-inhibitor therapy. Eur J Pharmacol 2010;628:164–70.
- Graham HK, Horn M, Trafford AW. Extracellular matrix profiles in the progression to heart failure. European Young Physiologists Symposium Keynote Lecture-Bratislava 2007. Acta Physiol (Oxf) 2008;194:3–21.
- Vandooren J, Van Den Steen PE, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol 2013;48:222–72.
- Woodiwiss AJ, Tsotetsi OJ, Sprott S, et al. Reduction in myocardial collagen cross-linking parallels left ventricular dilatation in rat models of systolic chamber dysfunction. Circulation 2001;103:155–60.
- Petrovic D. Cytopathological basis of heart failure–cardiomyocyte apoptosis, interstitial fibrosis and inflammatory cell response. Folia Biol (Praha) 2004;50:58–62.
- Segura AM, Frazier OH, Buja LM. Fibrosis and heart failure. Heart Fail Rev 2014;19:173–85.
- Askevold ET, Gullestad L, Dahl CP, et al. Aukrust P. Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure. Curr Heart Fail Rep 2014;11:146–55.
- Salvador AM, Nevers T, Velázquez F, et al. Intercellular adhesion molecule 1 regulates left ventricular leukocyte infiltration, cardiac remodeling, and function in pressure overload-induced heart failure. J Am Heart Assoc 2016;5:e003126.
- Rocha R, Martin-Berger CL, Yang P, et al. Selective aldosterone blockade prevents angiotensin ii/salt-induced vascular inflammation in the rat heart. Endocrinology 2011. doi: 10.1210/en.2002-220120
- Tokuyama H, Kelly DJ, Zhang Y, et al. Macrophage infiltration and cellular proliferation in the non-ischemic kidney and heart following prolonged unilateral renal ischemia. Nephron Physiol 2007;106:54–62.
- Fyhrquist F, Metsärinne K, Tikkanen I. Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. J Hum Hypertens 1995;9(Suppl 5):S19–24.
- Qiu Z-B, Xu H, Duan C, Chen X. Osteopontin is required for angiotensin II-induced migration of vascular smooth muscle cells. Pharmazie 2012;67:553–58.
- Kayama Y, Minamino T, Toko H, et al. Cardiac 12/15 lipoxygenase–induced inflammation is involved in heart failure. J Exp Med 2009;206:1565–74.
- Kamimura D, Ohtani T, Sakata Y, et al. Ca2+ entry mode of Na+/Ca2+ exchanger as a new therapeutic target for heart failure with preserved ejection fraction. Eur Heart J 2012;33:1408–16.
- Karmazyn M, Kilić A, Javadov S. The role of NHE-1 in myocardial hypertrophy and remodelling. J Mol Cell Cardiol 2008;44:647–53.
- Bishop T, Ratcliffe PJ. HIF hydroxylase pathways in cardiovascular physiology and medicine. Circ Res 2015;117:65–79.
- Semenza GL. Hypoxia-inducible factor 1 and cardiovascular disease. Annu Rev Physiol 2014;76:39–56.
- Yoshimura M, Yasue H, Ogawa H. Pathophysiological significance and clinical application of ANP and BNP in patients with heart failure. Can J Physiol Pharmacol 2001;79:730–35.
- Madamanchi C, Alhosaini H, Sumida A, Runge MS. Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. Int J Cardiol 2014;176:611–17.
- Rabkin SW, Klassen SS. Omapatrilat enhances adrenomedullin’s reduction of cardiomyocyte cell death. Eur J Pharmacol 2007;562:174–82.
- Nishikimi T, Yoshihara F, Horinaka S, et al. Chronic administration of adrenomedullin attenuates transition from left ventricular hypertrophy to heart failure in rats. Hypertension 2003;42:1034–41.
- Kinoshita T, Ishikawa Y, Arita M, et al. Antifibrotic response of cardiac fibroblasts in hypertensive hearts through enhanced TIMP-1 expression by basic fibroblast growth factor. Cardiovasc Pathol 2014;23:92–100.
- Moe GW, Rouleau JL, Nguyen QT, et al. Role of endothelins in congestive heart failure 1. 2003.
- Fujii S, Zhang L, Igarashi J, Kosaka H. L-arginine reverses p47phox and gp91phox expression induced by high salt in Dahl rats. Hypertension 2003;42:1014–20.
- Fujiu K, Nagai R. Fibroblast-mediated pathways in cardiac hypertrophy. J Mol Cell Cardiol 2014;70:64–73.
- Razeghi P, Young ME, Alcorn JL, et al. Metabolic gene expression in fetal and failing human heart. Circulation 2001;104:2923–31.
- Vescovo G, Ravara B, Gobbo V, et al. Skeletal muscle fibres synthesis in heart failure: Role of PGC-1α, calcineurin and GH. Int J Cardiol 2005;104:298–306.
- Bouhnik J, Richoux JP, Huang H, et al. Hypertension in Dahl salt-sensitive rats: Biochemical and immunohistochemical studies. Clin Sci (Lond) 1992;83:13–22.
- Anavekar NS, Solomon SD. Angiotensin II receptor blockade and ventricular remodelling. J Renin- Angiotensin- Aldosterone Syst 2005;6:43–48.
- Mei L, Huang Y, Lin J, et al. Increased cardiac remodeling in cardiac-specific Flt-1 receptor knockout mice with pressure overload. Cell Tissue Res 2015;362:389–98. Available at: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=26017635
- Kandalam V, Basu R, Moore L, et al. Lack of Tissue Inhibitor of Metalloproteinases 2 Leads to Exacerbated Left Ventricular Dysfunction and Adverse Extracellular Matrix Remodeling in Response to Biomechanical StressClinical Perspective. Circulation 2011;124.
- Dillmann W. Cardiac hypertrophy and thyroid hormone signaling. Heart Fail Rev 2010;15:125–32.
- Qiao A, Zhao Z, Zhang H, et al. Gene expression profiling reveals genes and transcription factors associated with dilated and ischemic cardiomyopathies. Pathol Res Pract 2017;213:548–57.
- Vanhoutte PM. COX-1 and vascular disease. Clin Pharmacol Ther 2009;86:212–15.
- Vitale P, Panella A, Scilimati A, Perrone MG. COX-1 Inhibitors: beyond structure toward therapy. Med Res Rev 2016;36:641–71.
- Kobayashi N, Ohno T, Yoshida K, et al. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats. Am J Hypertens 2008;21:576–81.
- Chugh S, Ouzounian M, Lu Z, et al. Pilot study identifying myosin heavy chain 7, desmin, insulin-like growth factor 7, and annexin A2 as circulating biomarkers of human heart failure. Proteomics 2013;13:2324–34.
- Anon. Review Manager(RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.